Core Viewpoint - Regeneron (REGN) reported Q4 2025 results that slightly exceeded market consensus, with no major surprises noted in the earnings report [2]. Financial Performance - The company provided expense guidance for 2026, indicating a focus on managing costs while maintaining growth [2]. Product Updates - Regeneron pre-announced Eylea, which is a significant product for the company, although specific details were not disclosed in the report [2].

Core Viewpoint - Regeneron Pharmaceuticals has received an "Outperform" rating upgrade from Raymond James, reflecting confidence in its future performance and an increased price target from $820 to $870 [1][5]. Financial Performance - Regeneron's recent Q4 2025 earnings call likely provided insights into key financial metrics such as revenue and profit margins, along with strategic plans and future expectations [2][5]. - The current stock price is $741.45, showing a slight decrease of 1.07% or $7.99, with trading volatility observed between $735.61 and $774.37 [3][5]. - Over the past year, the stock reached a high of $821.11 and a low of $476.49, indicating dynamic market performance [3]. Market Position - Regeneron has a market capitalization of approximately $76.58 billion, underscoring its significant presence in the biotechnology sector [4][5]. - The trading volume for the day is 1,313,119 shares on the NASDAQ exchange, reflecting active investor interest [4].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Regeneron Pharmaceuticals' executives expressed confidence in their experimental weight-loss drug, highlighting its potential cholesterol-lowering benefits as a competitive advantage in the market [1] Company Summary - The company is focusing on the dual benefits of weight loss and cholesterol reduction, which may enhance its market position as competition in the weight-loss drug sector intensifies [1]

Core Insights - Regeneron Pharmaceuticals reported Q4 2025 adjusted EPS of $11.44, exceeding the Zacks Consensus Estimate of $10.56, but down 5% from $12.07 in the previous year due to higher expenses [1][8] - Total revenues increased by 3% year over year to $3.9 billion, driven by higher sales of Eylea HD and increased profits from Dupixent, surpassing the Zacks Consensus Estimate of $3.8 billion [1][9] Financial Performance - Eylea sales in the U.S. fell 52% year over year to $577 million, primarily due to increased competition and market share loss, missing the Zacks Consensus Estimate of $592 million [5] - Eylea HD generated $506 million in the U.S., up 66% year over year, exceeding the Zacks Consensus Estimate of $477 million [9] - Total collaboration revenues reached $2 billion, a 22.6% increase from the previous year, beating the Zacks Consensus Estimate of $1.9 billion [9] - Sanofi's collaboration revenues rose 35% to $1.64 billion, driven by higher Dupixent sales, surpassing the Zacks Consensus Estimate of $1.6 billion [10] - Adjusted R&D expenses increased by 9% year over year to $1.3 billion, while adjusted SG&A expenses rose by 1% to $691 million [13] Product Developments - Eylea HD received FDA approval for additional indications, enhancing its market potential [7][17] - Dupixent was approved by the European Commission for chronic spontaneous urticaria, expanding its therapeutic applications [16] - Libtayo gained approval as an adjuvant treatment for cutaneous squamous cell carcinoma, broadening its market reach [19] Strategic Initiatives - Regeneron announced a new share repurchase program of up to $3 billion, with $1.5 billion remaining available as of December 31, 2025 [14] - The company is focusing on strengthening its oncology portfolio to diversify revenue streams, particularly following the label expansion of Libtayo [23] Market Position - Regeneron's shares have increased by 9.7% over the past year, compared to the industry's growth of 15.6% [2] - The company maintains a Zacks Rank 1 (Strong Buy), indicating strong market confidence [24]

Financial Performance - Regeneron Pharmaceuticals reported fourth-quarter adjusted earnings of $11.44 per share, a decrease of 5% year-over-year, surpassing the consensus estimate of $10.71 [1] - The company achieved sales of $3.88 billion, reflecting a 3% year-over-year increase, exceeding the consensus of $3.79 billion [1] Eylea Performance - U.S. net sales for Eylea HD and Eylea fell by 28% year-over-year to $1.08 billion, with $506 million from Eylea HD and $577 million from Eylea [2] - The FDA approved Eylea HD for macular edema following retinal vein occlusion, allowing for dosing every 8 weeks after an initial monthly period [2][3] Collaboration Revenue and New Investments - The increase in the company's share of profits from antibody commercialization was primarily driven by higher profits from Dupixent sales [4] - Regeneron plans to invest approximately $2 billion to develop a bulk manufacturing facility in Saratoga Springs, New York, in addition to over $7 billion in ongoing and planned domestic investments [4][5] Outlook - The company expects a fiscal 2026 GAAP gross margin of 79%–80% and an adjusted gross margin of 83%–84% [6] - Forecasted adjusted R&D expenses for 2026 are between $5.9 billion and $6.1 billion, with non-GAAP SG&A expenditures projected between $2.5 billion and $2.65 billion [6] - At the time of publication, Regeneron shares were down 0.32% at $747.05 [6]

Financial Data and Key Metrics Changes - Regeneron reported total revenues of $3.9 billion for Q4 2025, a 3% increase year-over-year, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income reaching $1.2 billion [40] - The company generated $4.1 billion in free cash flow for 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] Business Line Data and Key Metrics Changes - Dupixent achieved global net sales of $4.9 billion in Q4 2025, reflecting a 32% year-over-year growth [36] - EYLEA HD net product sales in the U.S. were $506 million in Q4, up 66% year-over-year, while EYLEA 2 mg sales declined 15% sequentially to $577 million [9][34] - Libtayo reported global net sales of $425 million in Q4, a 13% increase year-over-year, with strong demand across all approved indications [37] Market Data and Key Metrics Changes - Dupixent is now the most widely used innovative branded antibody medicine, with over 1.4 million patients globally [7] - EYLEA HD has become a significant part of Regeneron's anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with a strong market position in advanced non-small cell lung cancer [8][37] Company Strategy and Development Direction - Regeneron aims for at least four FDA approvals in 2026, including three for new molecular entities and the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional Phase III studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron is focused on advancing its pipeline in oncology, immunology, and ophthalmology, leveraging genetics to guide its R&D strategy [68][70] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with U.S. government agencies to reduce drug costs while ensuring patient access to innovative treatments [11] - The company anticipates continued growth in EYLEA HD and Dupixent, with significant opportunities in underpenetrated markets [36][7] - Management highlighted the importance of maintaining a competitive edge through innovative product development and strategic partnerships [70] Other Important Information - Regeneron is committed to helping patients afford their medications, matching a $60 million donation to a fund for retinal disease patients [10] - The company is actively engaging in discussions to address the long-standing imbalance in the distribution of costs for medical innovation [11] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future runway - Management refrained from providing additional comments but acknowledged Sanofi's positive outlook on Dupixent's future [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management emphasized a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management confirmed ongoing development of a potentially improved version of Dupixent, with plans to move it forward in clinical trials [76]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $3.9 billion, reflecting a 3% year-over-year increase, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income of $1.2 billion [40] - Regeneron's share of collaboration profits from Sanofi grew 42% year-over-year, primarily due to Dupixent [41] Business Line Data and Key Metrics Changes - Global net product sales for Dupixent reached $4.9 billion in Q4 2025, a 32% increase year-over-year [7] - Libtayo's global net sales were $425 million in Q4 2025, up 13% year-over-year [37] - EYLEA HD net product sales in the U.S. were $506 million in Q4 2025, representing a 66% increase [9] Market Data and Key Metrics Changes - Dupixent is now approved in eight indications, with over 1.4 million patients on therapy globally, indicating significant market penetration potential [7] - EYLEA HD has become a growing proportion of Regeneron's total anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with strong demand growth across all approved indications [37] Company Strategy and Development Direction - Regeneron anticipates at least four FDA approvals in 2026, including three for new molecular entities and one for the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional phase 3 studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron aims to continue capital deployment for share repurchases, dividends, and complementary business development to drive long-term shareholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with the U.S. government to reduce drug costs while ensuring access to innovative treatments [11] - The company highlighted the importance of its innovative pipeline, with multiple pivotal readouts and regulatory milestones expected in 2026 [30] - Management emphasized the competitive advantages of Dupixent, including its efficacy and safety profile compared to other immunomodulators [59] Other Important Information - Regeneron generated $4.1 billion in free cash flow in 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] - The company initiated a quarterly dividend, providing additional flexibility to return capital to shareholders [45] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future potential - Management refrained from providing additional comments but acknowledged Sanofi's commentary on extending the IP runway [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management confirmed a commitment to a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management discussed the potential of a "souped-up" version of Dupixent that may offer longer-lasting effects and other advantages, with plans to move it forward in clinical development [76]

Regeneron Pharmaceuticals (NasdaqGS:REGN) Q4 2025 Earnings call January 30, 2026 08:30 AM ET Speaker4Welcome to the Regeneron Pharmaceuticals fourth quarter 2025 earnings conference call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President of Investor Relations. ...

Regeneron Corporate Presentation J A N U A R Y 2 0 2 6 2 Integrating Genetics, Proteomics, and Big Data World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that i ...